Related references
Note: Only part of the references are listed.Full-Length Plasmodium falciparum Circumsporozoite Protein Administered with Long-Chain Poly(I.C) or the Toll-Like Receptor 4 Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent Antibody and CD4+ T Cell Immunity and Protection in Mice
Kathrin Kastenmueller et al.
INFECTION AND IMMUNITY (2013)
Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells
Susan L. Baldwin et al.
JOURNAL OF IMMUNOLOGY (2013)
A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age
Alphonse Ouedraogo et al.
PLOS ONE (2013)
Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE plus GLA) adjuvant
John J. Treanor et al.
VACCINE (2013)
Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults
C. Buddy Creech et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines
Christopher B. Fox et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older Adults
Hayedeh Behzad et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Sara Mian-McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
Michael C. Keefer et al.
PLOS ONE (2012)
A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E
Francis M. Ndungu et al.
PLOS ONE (2012)
Reliable protein production in a Pseudomonas fluorescens expression system
Diane M. Retallack et al.
PROTEIN EXPRESSION AND PURIFICATION (2012)
Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guerin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice
Charles Arama et al.
VACCINE (2012)
KSAC, a Defined Leishmania Antigen, plus Adjuvant Protects against the Virulence of L. major Transmitted by Its Natural Vector Phlebotomus duboscqi
Regis Gomes et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial
Kwaku Poku Asante et al.
LANCET INFECTIOUS DISEASES (2011)
Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate
Hillarie Plessner Windish et al.
VACCINE (2011)
The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert
Katarina Radosevic et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
Ryan C. Anderson et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2010)
Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice
Takayuki Shiratsuchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Rhea N. Coler et al.
PLOS ONE (2010)
Structure of the Plasmodium falciparum Circumsporozoite Protein, a Leading Malaria Vaccine Candidate
Matthew L. Plassmeyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Protection against a Malaria Challenge by Sporozoite Inoculation.
Meta Roestenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The development of the RTS,S malaria vaccine candidate: challenges and lessons
W. R. Ballou
PARASITE IMMUNOLOGY (2009)
The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity
Silayuv E. Bongfen et al.
VACCINE (2009)
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice
Joseph P. Shott et al.
VACCINE (2008)
Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells
Alida Coppi et al.
CELL HOST & MICROBE (2007)
Viral vector vaccines make memory T cells against malaria
Arturo Reyes-Sandoval et al.
IMMUNOLOGY (2007)
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone
V. Ann Stewart et al.
INFECTION AND IMMUNITY (2007)
T-cell immunity generated by recombinant adenovirus vaccines
Teng Chih Yang et al.
EXPERT REVIEW OF VACCINES (2007)
The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites
Kota Arun Kumar et al.
NATURE (2006)
Combination DNA plus protein HIV vaccines
Shan Lu
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2006)
Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice
OJAE Ophorst et al.
INFECTION AND IMMUNITY (2006)
The global distribution of clinical episodes of Plasmodium falciparum malaria
RW Snow et al.
NATURE (2005)
The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion
A Coppi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial
PL Alonso et al.
LANCET (2004)
Prime-boost strategies for malaria vaccine development
SJ Dunachie et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2003)
Cutting edge:: A new tool to evaluate human pre-erythrocytic malaria vaccines:: Rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein
C Persson et al.
JOURNAL OF IMMUNOLOGY (2002)
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites
SL Hoffman et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Binding and invasion of liver cells by Plasmodium falciparum sporozoites - Essential involvement of the amino terminus of circumsporozoite protein
D Rathore et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR
O Bruña-Romero et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2001)
Share Paper
